Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Blood (2024) 143 (4): 336–341.

https://doi.org/10.1182/blood.2023021579

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of Somatic Second Hit and Comutations in Myeloid Neoplasms with Germline DDX41 Mutations

Guilherme Mendes Sapinho, Pramila Krishnamurthy, Guy Hannah, Shreyans Gandhi, Victoria Potter, Mili Shah, Nicholas Lea, Clair Engelbrecht, Heidre Bezuidenhout, Katie Snape, Steve Best, Austin Kulasekararaj

Blood (2023) 142 (Supplement 1): 6446.

https://doi.org/10.1182/blood-2023-189451

Published: 2023

Journal Articles

Real-World Mobilization, Harvest, and Transplant Outcomes in Newly Diagnosed Multiple Myeloma Patients Receiving D-VTd: A UK Centre Experience

Blood (2023) 142 (Supplement 1): 4971.

https://doi.org/10.1182/blood-2023-177624

Published: 2023

Journal Articles

Outcome Prediction in DDX41 -Mutant Myelodysplastic Syndromes Is Not Possible with General Disease Schemes and Requires a Dedicated Risk Scoring System

Carmelo Gurnari, Hideki Makishima, Arda Durmaz, Ryunosuke Saiki, Guilherme Mendes Sapinho, Alex Bataller, Lukasz P. Gondek, Yasuhito Nannya, Steve Best, Pramila Krishnamurthy, Hussein Awada, Enrico Attardi, Valeria Visconte, Maria Teresa Voso, Amy E. DeZern, Guillermo Garcia-Manero, Austin Kulasekararaj, Jaroslaw P. Maciejewski, Seishi Ogawa

Blood (2023) 142 (Supplement 1): 316.

https://doi.org/10.1182/blood-2023-178116

Published: 2023

Journal Articles

Double, double, TP53, and trouble in myelofibrosis

Pramila Krishnamurthy

Blood (2023) 141 (23): 2793–2795.

https://doi.org/10.1182/blood.2023020421

Published: 2023

Journal Articles

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Hideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, Sophia Korotev, Carmelo Gurnari, June Takeda, Yukihide Momozawa, Steve Best, Pramila Krishnamurthy, Tetsuichi Yoshizato, Yoshiko Atsuta, Yusuke Shiozawa, Yuka Iijima-Yamashita, Kenichi Yoshida, Yuichi Shiraishi, Yasunobu Nagata, Nobuyuki Kakiuchi, Makoto Onizuka, Kenichi Chiba, Hiroko Tanaka, Ayana Kon, Yotaro Ochi, Masahiro M. Nakagawa, Rurika Okuda, Takuto Mori, Akinori Yoda, Hidehiro Itonaga, Yasushi Miyazaki, Masashi Sanada, Takayuki Ishikawa, Shigeru Chiba, Hisashi Tsurumi, Senji Kasahara, Carsten Müller-Tidow, Akifumi Takaori-Kondo, Kazuma Ohyashiki, Toru Kiguchi, Fumihiko Matsuda, Joop H. Jansen, Chantana Polprasert, Piers Blombery, Yoichiro Kamatani, Satoru Miyano, Luca Malcovati, Torsten Haferlach, Michiaki Kubo, Mario Cazzola, Austin G. Kulasekararaj, Lucy A. Godley, Jaroslaw P. Maciejewski, Seishi Ogawa

Blood (2023) 141 (5): 534–549.

https://doi.org/10.1182/blood.2022018221

Published: 2023

Includes: Supplemental data

Journal Articles

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

Blood (2022) 140 (Supplement 1): 2033–2035.

https://doi.org/10.1182/blood-2022-159467

Published: 2022

Journal Articles

Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies

Hideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, Sophia C. Korotev, Carmelo Gurnari, June Takeda, Yukihide Momozawa, Steve Best, Pramila Krishnamurthy, Tetsuichi Yoshizato, Yoshiko Atsuta, Yusuke Shiozawa, Yuka Iijima-Yamashita, Kenichi Yoshida, Yuichi Shiraishi, Yasunobu Nagata, Nobuyuki Kakiuchi, Makoto Onizuka, Kenichi Chiba, Hiroko Tanaka, Ayana Kon, Yotaro Ochi, Masahiro Marshall Nakagawa, Rurika Okuda, Takuto Mori, Akinori Yoda, Hidehiro Itonaga, Yasushi Miyazaki, Masashi Sanada, Takayuki Ishikawa, Shigeru Chiba, Hisashi Tsurumi, Senji Kasahara, Carsten Müller-Tidow, Akifumi Takaori-Kondo, Kazuma Ohyashiki, Toru Kiguchi, Fumihiko Matsuda, Joop H. Jansen, Chantana Polprasert, Piers Blombery, Yoichiro Kamatani, Satoru Miyano, Luca Malcovati, Torsten Haferlach, Michiaki Kubo, Mario Cazzola, Austin Kulasekararaj, Lucy A. Godley, Jaroslaw P. Maciejewski, Seishi Ogawa

Blood (2022) 140 (Supplement 1): 208–210.

https://doi.org/10.1182/blood-2022-158851

Published: 2022

Journal Articles

Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease - Real-World Data from a UK-Wide Programme

Blood (2022) 140 (Supplement 1): 9016–9018.

https://doi.org/10.1182/blood-2022-167097

Published: 2022

Journal Articles

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

Blood (2022) 140 (Supplement 1): 2002–2004.

https://doi.org/10.1182/blood-2022-159503

Published: 2022

Journal Articles

Post-Transplant MRD Status and T Cell Chimerism Predict Outcomes in Patients Allografted for AML/MDS-a Prospective Analysis from the UK NCRI Figaro Trial

Blood (2021) 138 (Supplement 1): 415.

https://doi.org/10.1182/blood-2021-149269

Published: 2021

Journal Articles

Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service

Blood (2021) 138 (Supplement 1): 2321.

https://doi.org/10.1182/blood-2021-149685

Published: 2021

Journal Articles

Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service

Blood (2021) 138 (Supplement 1): 1254.

https://doi.org/10.1182/blood-2021-150169

Published: 2021

Journal Articles

Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program

Blood (2021) 138 (Supplement 1): 1942.

https://doi.org/10.1182/blood-2021-146061

Published: 2021

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

Donor Lymphocyte Infusions Correct Deficiency of Naive T Cells and Improve T-Cell Competence after Allogeneic Haematopoietic Stem Cell Transplantation with Lymphocyte Depletion

Monera Al Rukhayes, Victoria T Potter, Pilar Perez-Abellan, Jesus Feliu, Lajos Floro, Ruby Quartey-Papafio, Farzin Farzaneh, Pramila Krishnamurthy, Jennifer Clay, Carmel Rice, Antonio Pagliuca, MBBS MA FRCP FRCPath, Ghulam J Mufti, Linda D Barber

Blood (2016) 128 (22): 2233.

https://doi.org/10.1182/blood.V128.22.2233.2233

Published: 2016

Journal Articles

Adverse Effect of Very Poor Cytogenetics and Monosomal Karyotype On Outcomes Following T-Deplete Reduced Intensity Conditioned Stem Cell Transplant for MDS and AML.

Pramila Krishnamurthy, MA MRCP FRCPath, Victoria T Potter, MBBS, FRCPA, FRACP, Austin G Kulasekararaj, Victor Noriega, Hugues de Lavallade, Robin M. Ireland, FRCP, FRCPath, Stephen Devereux, FRCP, FRCPath, Judith C. W. Marsh, MD, PhD, Robert E. Marcus, MBBS, FRCP, FRCPath, Barbara Czepulkowski, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD

Blood (2012) 120 (21): 3141.

https://doi.org/10.1182/blood.V120.21.3141.3141

Published: 2012

Journal Articles

HCT-CI Is Not a Useful Predictor for Non Relapse Mortality in Older Patients (>60 years old) Receiving RIC Transplant for AML or MDS

Victor Noriega, MD, Hugues de Lavallade, MD, Victoria T Potter, MBBS, FRCPA, FRACP, Pramila Krishnamurthy, Judith C. W. Marsh, Prof MD PhD, Stephen Devereux, FRCP, FRCPath, Ph.D., Robert E. Marcus, MBBS, FRCP, FRCPath, Kavita Raj, Donal McLornan, MD, PhD, Anjum Bashir Khan, MBChB, MRCP, Sangeeta Atwal, MBBS MRCP FRCPath, Robin M. Ireland, FRCP, FRCPath, Deborah Yallop, BSc, FRCPath, MB, BS, MRCP, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J Mufti, FRCP, FRCPath, M.D.

Blood (2012) 120 (21): 4158.

https://doi.org/10.1182/blood.V120.21.4158.4158

Published: 2012

Journal Articles

Telomere Length In MDS Patients Bone Marrow Is Highly Correlated with Complex Cytogenetics, IPSS Risk Groups and Transfusion Dependency,

Jie Jiang, PhD, Austin G Kulasekararaj, Pramila Krishnamurthy, Alexander E Smith, PhD, Syed A Mian, Shreyans Gandhi, Janet Hayden, Joop Gaken, Modupe Elebute, Robin M. Ireland, FRCP, FRCPath, ZiYi Lim, MD, Judith C. W. Marsh, Prof MD PhD, Ghulam J. Mufti, MD

Blood (2011) 118 (21): 3826.

https://doi.org/10.1182/blood.V118.21.3826.3826

Published: 2011

Journal Articles

TP53 Mutations Are Restricted Predominantly to 5q- Syndrome and Myelodysplastic Syndrome Patients with Complex Cytogenetics, and Correlate with Adverse Prognosis

Austin G Kulasekararaj, Alexander E Smith, PhD, Syed A Mian, Pramila Krishnamurthy, Azim M Mohamedali, PhD, Nicholas C Lea, PhD, Janet Hayden, Joop Gaken, Modupe Elebute, Robin M. Ireland, FRCP, FRCPath, Sabine Pomplun, ZiYi Lim, MD, Judith C. W. Marsh, Prof MD PhD, Ghulam J. Mufti, MD

Blood (2011) 118 (21): 792.

https://doi.org/10.1182/blood.V118.21.792.792

Published: 2011

NARROW

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Impact of Somatic Second Hit and Comutations in Myeloid Neoplasms with Germline DDX41 Mutations

Real-World Mobilization, Harvest, and Transplant Outcomes in Newly Diagnosed Multiple Myeloma Patients Receiving D-VTd: A UK Centre Experience

Outcome Prediction in DDX41 -Mutant Myelodysplastic Syndromes Is Not Possible with General Disease Schemes and Requires a Dedicated Risk Scoring System

Double, double, TP53, and trouble in myelofibrosis

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies

Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease - Real-World Data from a UK-Wide Programme

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

Post-Transplant MRD Status and T Cell Chimerism Predict Outcomes in Patients Allografted for AML/MDS-a Prospective Analysis from the UK NCRI Figaro Trial

Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service

Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service

Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Donor Lymphocyte Infusions Correct Deficiency of Naive T Cells and Improve T-Cell Competence after Allogeneic Haematopoietic Stem Cell Transplantation with Lymphocyte Depletion

Adverse Effect of Very Poor Cytogenetics and Monosomal Karyotype On Outcomes Following T-Deplete Reduced Intensity Conditioned Stem Cell Transplant for MDS and AML.

HCT-CI Is Not a Useful Predictor for Non Relapse Mortality in Older Patients (>60 years old) Receiving RIC Transplant for AML or MDS

Telomere Length In MDS Patients Bone Marrow Is Highly Correlated with Complex Cytogenetics, IPSS Risk Groups and Transfusion Dependency,

TP53 Mutations Are Restricted Predominantly to 5q- Syndrome and Myelodysplastic Syndrome Patients with Complex Cytogenetics, and Correlate with Adverse Prognosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only